Orphai Therapeutics Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
Previously recorded as AI Therapeutics, Inc. (to 2023)
1
Ending by 2030
Nov 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 5, 2027The maintenance fee for Rapamycin for the Treatment of Lymphangioleiomyomatosis (US 11,744,797) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
- 1 fee due Aug 25, 2027The maintenance fee for Combinations of a Mithramycin Analogue and Another Chemotherapeutic Agent for the Treatment of Triple Negative Breast Cancer (US 10,568,899) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Combination Therapy with Apilimod and Glutamatergic Agents (US 11,957,688) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,772,253 | Aureolic Acid Derivatives, the Method for Preparation Thereof and the Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,307,370 | Rapamycin for the Treatment of Lymphangioleiomyomatosis In force · High confidence | In force | High confidence | |
| US 10,307,371 | Rapamycin for the Treatment of Lymphangioleiomyomatosis In force · Low confidence | In force | Low confidence | |
| US 11,123,289 | Rapamycin for the Treatment of Lymphangioleiomyomatosis In force · Medium confidence | In force | Medium confidence | |
| US 12,171,874 | Rapamycin for the Treatment of Lymphangioleiomyomatosis In force · Low confidence | In force | Low confidence | |
| US 11,744,797 | Rapamycin for the Treatment of Lymphangioleiomyomatosis In force · Low confidence | In force | Low confidence | |
| US 10,179,135 | Apilimod Compositions and Methods for Using Same In force · High confidence | In force | High confidence | |
| US 11,103,449 | An Inhalable Rapamycin Formulation for Treating Age-Related Conditions In force · High confidence | In force | High confidence | |
| US 11,648,199 | Inhalable Rapamycin Formulation for Treating Age-Related Conditions In force · Medium confidence | In force | Medium confidence | |
| US 11,491,143 | Inhalable Rapamycin Formulation for the Treatment of Pulmonary Hypertension In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 18: 5 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending